Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer : study protocol of the FORCE trial
Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with non-squamous...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 November 2019
|
| In: |
BMC cancer
Year: 2019, Volume: 19 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-6205-0 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-019-6205-0
|
| Author Notes: | Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas and Stefan Rieken |
| Summary: | Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patients with non-squamous non-small cell lung carcinoma (NSCLC) has significantly improved outcome in this cohort. Preclinical and early clinical data suggest that the combination of photon radiation with programmed death-1 (PD-1) targeting immunotherapies may promote a strong and durable immune response against tumor manifestations both within and beyond radiation targets. |
|---|---|
| Item Description: | Gesehen am 07.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-6205-0 |